¸Þµð¾÷

´ëÇк´¿ø Çѹ溴¿ø
Á¾ÇÕº´¿ø ³ëÀκ´¿ø
°Ô½ÃÆÇ
°Ç°­Á¤º¸
º´¿ø¾à±¹Á¤º¸
Èú¸µ½ºÅ丮
Áúº´Á¤º¸
ÀǾàÇ°Á¤º¸
ÀÇÇм­Àû
ÀÓ´ëºÐ¾ç¸Å¸Å
¿¬¼ö°­ÁÂ
±³À°Á¤º¸
¸ÞµðÅå
´ëÇк´¿ø Á¾ÇÕº´¿ø Çѹ溴¿ø Ä¡°úº´¿ø ÇÑÀÇ¿ø ³ëÀÎÀü¹®º´¿ø º¸°Ç¼Ò
¼­¿ï ºÎ»ê ÀÎõ ´ë±¸ ´ëÀü ±¤ÁÖ ¿ï»ê °æ±â °­¿ø ÃæºÏ Ãæ³² °æºÏ °æ³² ÀüºÏ Àü³² Á¦ÁÖ ¼¼Á¾
Ä¡°ú ¾È°ú ÇǺΰú ¼ºÇü¿Ü°ú »êºÎÀΰú ºñ´¢±â°ú ¿Ü°ú ³»°ú Á¤Çü¿Ü°ú À̺ñÀÎÈÄ°ú ¼Ò¾Æ°ú ¾à±¹

¸ñ·Ï ¼öÁ¤ »èÁ¦

(¿Â¶óÀÎ)´ëÇѺÎÀÎÁ¾¾çÇÐȸ Á¦ 27Â÷ Ãß°èÇмú´ëȸ : 2021-10-30

ÃßõÇϱâ
¿¬¼ö°­Á À̹øÁÖ BEST
 
(¿Â¶óÀÎ)´ëÇѺÎÀÎÁ¾¾çÇÐȸ Á¦ 27Â÷ Ãß°èÇмú´ëȸ : 2021-10-30
±³À°ÀÏÀÚ : 2021-10-30
±³À°Àå¼Ò : ¿Â¶óÀΠ 
±³À°ÁÖÁ¦ : (¿Â¶óÀÎ)´ëÇѺÎÀÎÁ¾¾çÇÐȸ Á¦ 27Â÷ Ãß°èÇмú´ëȸ
ÁÖÃÖ±â°ü : ´ëÇѺÎÀÎÁ¾¾çÇÐȸ
´ã´çÀÚ : ÇѼ¼¹Ì
¿¬¶ôó : 02-512-0044  
À̸ÞÀÏ : office@sgo.or.kr      
±³À°Á¾·ù : »êºÎÀΰú      
Âü¼®¿¹»óÀοø : 300¸í
Èñ¸ÁÆòÁ¡ : 6Á¡  
Áö¿ª : ¼­¿ïƯº°½Ã
±³À°½Ã°£ : 6 ½Ã°£ 45ºÐ  
¼¼ºÎ¼ö°­·á : 60,000¿ø      
ºñ°í Àü¹®ÀÇ 60,000 Àü°øÀÇ 45,000 ÀϹÝÀÇ,¿¬±¸¿ø,°£È£»ç 30,000 ÁÂÀå,¿¬ÀÚ,¸¸65¼¼ÀÌ»ó ¹«·á      

±¸ºÐ ¿ùÀÏ °­ÀǽǠ½Ã°£ ±³À°Á¦¸ñ  °­»ç¸í(¼Ò¼Ó) Çʼö°ú¸ñ
±âŸ 10-30 ¿Â¶óÀΠ08:50~09:00 Opening Remarks  ±è¿µÅÂ(´ëÇѺÎÀÎÁ¾¾çÇÐȸ ȸÀå) 
±âŸ 10-30 ¿Â¶óÀΠ09:00~09:05 Á¦5ȸ ºÎÀÎÁ¾¾çÀÇÇлó, JGO Best reviewer ½Ã»ó½Ä  () 
±³À°½Ã°£ 10-30 ¿Â¶óÀΠ09:05~09:10 ºÎÀÎÁ¾¾çÀÇÇлó Çмú´ë»ó ¼ö»óÀÚ ¹ßÇ¥  ¼ö»óÀÚ() 
±³À°½Ã°£ 10-30 ¿Â¶óÀΠ09:10~09:15 ºÎÀÎÁ¾¾çÀÇÇлó ÀþÀºÀÇÇÐÀÚ ¼ö»óÀÚ ¹ßÇ¥  ¼ö»óÀÚ() 
±âŸ 10-30 ¿Â¶óÀΠ09:15~09:20 ¸í¿¹È¸¿øÁõ ¼ö¿©  Daisuke Aok(Keio University, Japan) 
±³À°½Ã°£ 10-30 ¿Â¶óÀΠ09:20~09:40 SOC-1 (Ovarian Cancer)  Rongyu Zang(Fudan University Zhongshan Hospital, China) 
Åä·Ð 10-30 ¿Â¶óÀΠ09:40~09:50 Designated discussion  ÀÌÀ¯¿µ(¼º±Õ°üÀÇ´ë) 
±³À°½Ã°£ 10-30 ¿Â¶óÀΠ09:50~10:10 KEYNOTE-775 (Endometrial Cancer )  Vicky Makker(Memorial Sloan Kettering Cancer Center, USA) 
Åä·Ð 10-30 ¿Â¶óÀΠ10:10~10:20 Designated discussion  ±è¹Ì°æ(ÀÌÈ­ÀÇ´ë) 
±³À°½Ã°£ 10-30 ¿Â¶óÀΠ10:20~10:40 KEYNOTE-826 (Cervical Cancer)  Nicoletta Colombo(Istituto Europeo di Oncologia, Italia) 
Åä·Ð 10-30 ¿Â¶óÀΠ10:40~10:50 Designated discussion  ±èÈñ½Â(¼­¿ïÀÇ´ë) 
È޽Ġ10-30 ¿Â¶óÀΠ10:50~11:00 Break  () 
±³À°½Ã°£ 10-30 ¿Â¶óÀΠ11:00~11:15 Do you think First-line maintenance to all patients with ovarian cancer? - Pros  À̼ºÁ¾(°¡Å縯ÀÇ´ë) 
±³À°½Ã°£ 10-30 ¿Â¶óÀΠ11:15~11:30 Do you think First-line maintenance to all patients with ovarian cancer? - Cons  ¹Ú±Ç¿À(ºÎ»êÀÇ´ë Á¾¾ç³»°ú) 
±³À°½Ã°£ 10-30 ¿Â¶óÀΠ11:30~11:50 Selection of surgery in patients with recurrent ovarian cancer  À̸¶¸®¾Æ(¼­¿ïÀÇ´ë) 
±³À°½Ã°£ 10-30 ¿Â¶óÀΠ11:50~12:00 Case study  ÃÖ¹Îö(Â÷ÀÇ´ë) 
±³À°½Ã°£ 10-30 ¿Â¶óÀΠ12:00~12:20 Molecular classification of endometrial cancer: selecting adjuvant therapy  È«ÁøÈ­(°í·ÁÀÇ´ë) 
±³À°½Ã°£ 10-30 ¿Â¶óÀΠ12:20~12:30 Case study  ³²ÀºÁö(¿¬¼¼ÀÇ´ë) 
±³À°½Ã°£ 10-30 ¿Â¶óÀΠ12:30~12:50 Real-world ovarian cancer Niraparib patient case studies  Richard T Penson MD MRCP(Medicine Harvard Medical School) 
±³À°½Ã°£ 10-30 ¿Â¶óÀΠ12:50~13:10 ONBEVZI: The Arrival of Bevacizumab Biosimilar in Gynecologic Cancer  ¼­µ¿ÈÆ(¼­¿ïÀÇ´ë) 
½Ä»ç 10-30 ¿Â¶óÀΠ13:10~13:50 Lunch  () 
±âŸ 10-30 ¿Â¶óÀΠ13:50~14:05 ºÎÀÎ¾Ï ¼ö¼úµ¿ÀǼ­ °øûȸ-°³¿ä ¹× ¾ÏÁ¾º° µ¿ÀǼ­ ¹ßÇ¥  ½É»çÀ§¿øȸ(ºÎÀÎÁ¾¾çÇÐȸ) 
±âŸ 10-30 ¿Â¶óÀΠ14:05~14:20 Discussion  () 
±³À°½Ã°£ 10-30 ¿Â¶óÀΠ14:20~14:40 Relevance of Artificial intelligence-Surgery  Á¤Ã¢¿í(¼­¿ïÀÇ´ë ºñ´¢ÀÇÇаú) 
±³À°½Ã°£ 10-30 ¿Â¶óÀΠ14:40~15:00 Relevance of Artificial intelligence-Radiology  ±èÈÖ¿µ(¿¬¼¼ÀÇ´ë ¿µ»óÀÇÇаú) 
±³À°½Ã°£ 10-30 ¿Â¶óÀΠ15:00~15:20 Relevance of Artificial intelligence-Pathology  Á¤¿ä¼Á(°¡Å縯ÀÇ´ë º´¸®°ú) 
Åä·Ð 10-30 ¿Â¶óÀΠ15:20~15:40 Designated discussion  À̽ÅÈ­/°øÅ¿í(¿ï»êÀÇ´ë/¾ÆÁÖÀÇ´ë) 
È޽Ġ10-30 ¿Â¶óÀΠ15:40~15:55 Break  () 
±³À°½Ã°£ 10-30 ¿Â¶óÀΠ15:55~16:10 Domestic approach to HRD testing  Á¶ÀºÇØ(³ì½ÊÀÚÁö³ð¿¬±¸¼Ò) 
Åä·Ð 10-30 ¿Â¶óÀΠ16:10~16:20 Designated discussion  ÀÓ¸íö(±¹¸³¾Ï¼¾ÅÍ) 
±³À°½Ã°£ 10-30 ¿Â¶óÀΠ16:20~16:40 Management of side effects through patients education  ±è¹Î±Ô(¼º±Õ°üÀÇ´ë) 
±³À°½Ã°£ 10-30 ¿Â¶óÀΠ16:40~16:50 Case study  ½É½ÂÇõ(°Ç±¹ÀÇ´ë) 
±³À°½Ã°£ 10-30 ¿Â¶óÀΠ16:50~17:10 Breaking bad news  À¯Àº½Â(°í·Á»çÀ̹ö´ë) 
±³À°½Ã°£ 10-30 ¿Â¶óÀΠ17:10~17:30 End of life care  ÀÓ°¡¿ø(µ¿±¹ÀÇ´ë) 
±âŸ 10-30 ¿Â¶óÀΠ17:30~17:50 Closing Remarks & Á¤±âÃÑȸ  () 
ÆÄ¿ö¸µÅ© ±¤°íµî·Ï
ÀÌ °Ô½Ã¹°À» ÃßõÇÕ´Ï´Ù.
¸Þµð¾÷
" (¿Â¶óÀÎ)´ëÇѺÎÀÎÁ¾¾çÇÐȸ Á¦ 27Â÷ Ãß°èÇмú´ëȸ : 2021-10-30""ÀÇ ÀÌ¿ëÈı⳪ Ãßõ´ñ±ÛÀ» ³²°Ü À¯¿ëÇÑ Á¤º¸·Î °øÀ¯ÇսôÙ. ^^
¡å
ÀÌ °Ô½Ã¹°À» ÃßõÇÕ´Ï´Ù.
 
¸ñ·Ï ¼öÁ¤ »èÁ¦
ÀÌÀü±Û ´ëÇѾȸ鼺ÇüÀç°ÇÇÐȸ (¿Â¶óÀÎ) The Nose: Inside & Outside 2021 SNUH Course on Rhinoplasty : 2021-10-30
´ÙÀ½±Û ´ëÇѽŰæÁýÁßÄ¡·áÇÐȸ Á¦3ȸ ½Å°æºñ»óÆÀ ½ÉÆ÷Áö¾ö : 2021-10-30
¹øÈ£ Á¦¸ñ Ãßõ Á¶È¸ µî·ÏÀÏ
20895 ¼­¿ï ´ëÇѼҾƽÅÀåÇÐȸ (¿Â¶óÀÎ) 2024³â ¼Ò¾Æ½ÅÀå Post-graduate education course : 2024-07-01 0 4 2024-05-28
20894 ´ëÀü Ãæ³²´ëÇб³º´¿ø 2024³â °³¿øÀÇ¿Í ÇÔ²²ÇÏ´Â ³»°ú ¿¬¼ö°­Á : 2024-06-30 0 7 2024-05-28
20893 ¼­¿ï ´ëÇѳúÁ¹ÁßÇÐȸ 6¿ù º¸¼ö±³À° : 2024-06-30 0 112 2024-05-27
20892 ¼­¿ï (¿Â¶óÀÎ)Á¦22Â÷ ¼­¿ïƯº°½ÃÀÇ»çȸ Çмú´ëȸ : 2024-06-30 0 17 2024-05-27
20891 °æ±â (¿Â¶óÀÎ)Á¦21Â÷ °æ±âµµÀÇ»çȸ ¿Â¶óÀÎ Çмú´ëȸ : 2024-06-30 0 75 2024-05-27
20890 Àü³² 2024³â ´ëÇÑ´ëÀåÇ×¹®ÇÐȸ ¿¬¼ö°­Á : 2024-06-30 0 12 2024-05-27
20889 Ãæ³² ´ëÇÑÁ¤Çü¿Ü°úÃÊÀ½ÆÄÇÐȸ - Á¦19Â÷ Ãá°èÇмú´ëȸ ¹× Á¦38Â÷ ±Ù°ñ°Ý°è ÃÊÀ½ÆÄ¿öÅ©¼¥ (Basic Course) : 2024-06-30 0 8 2024-05-27
20888 ºÎ»ê Á¦3ȸ ´ëÇÑÅõ¼®Çùȸ ºÎ»êÁöȸ ½ÉÆ÷Áö¾ö : 2024-06-29 0 7 2024-05-27
20887 ¼­¿ï Çѱ¹ÁöÁú¤ýµ¿¸Æ°æÈ­ÇÐȸ Á¦7ȸ A to Z (Atherosclerosis to Zero) ¿¬¼ö°­Á ÇÁ·Î±×·¥ : 2024-06-29 0 27 2024-05-27
20886 °æ±â 2024³âµµ ³²¾çÁÖ½ÃÀÇ»çȸ Çмú´ëȸ : 2024-06-29 0 3 2024-05-27
20885 ¼­¿ï (¿Â¶óÀÎ)Á¦14ȸ ´ëÇÑ°¨¿°ÇÐȸ Æò»ý±³À° ÇÁ·Î±×·¥ °¨¿°Áúȯ ÃÖ½ÅÁö°ß : 2024-06-29 0 8 2024-05-27
20884 ¼­¿ï Á¦24Â÷ ´ëÇѽÅÀåÇÐȸ ½ÅÀ̽Ŀ¬±¸È¸ ¿¬¼ö°­Á : 2024-06-29 0 1 2024-05-27
20883 ¼­¿ï 2024 ¼±Ãµ¼º Ⱦ°æ¸· Å»Àå ÄÚȣƮ (K-CDH) ±³À°¼¼¹Ì³ª : 2024-06-29 0 10 2024-05-27
20882 ¼­¿ï 2024 ¿©¼º½ÉÀåÁúȯ¿¬±¸È¸ ÇÏ°è ½ÉÆ÷Áö¾ö : 2024-06-29 0 7 2024-05-27
20881 °­¿ø 2024 ³âµµ Á¤Çü¿Ü°úÇб³½Ç °³¿øÀÇ¿¬¼ö°­Á : 2024-06-29 0 11 2024-05-27
1 | 2 | 3 | 4 | 5 | 6 | 7 | 8 | 9 | 10
 
Ä¿¹Â´ÏƼ
°Ô½ÃÆÇ
°Ç°­Á¤º¸
º´¿ø¾à±¹
Èú¸µ½ºÅ丮
Áúº´Á¤º¸
ÀǾàÇ°Á¤º¸
ÀÇÇм­Àû
ÀÓ´ë¸Å¸Å
¿¬¼ö°­ÁÂ
±³À°Á¤º¸
º´¿øȨÆäÀÌÁö
¸ÞµðÅå
ÇÑÀÇ¿ø
¼ºÇü¿Ü°ú
Ä¡°ú
¾È°ú
¿©¼ºº´¿ø
³»°ú
Á¤Çü¿Ü°ú
ÇǺΰú
¼Ò¾Æ°ú
À̺ñÀÎÈÄ°ú
ºñ´¢ÀÇÇаú
¿ä¾çº´¿ø
ÀçÈ°ÀÇÇаú
µ¿¹°º´¿ø
±âŸº´ÀÇ¿ø
Ãë¾÷°ü·Ã
Áö¿ø¼­¾ç½Ä
¼­·ù¾ç½Ä
¸Þµð¾÷ ¸ð¹ÙÀÏÀ¥
¸Þµð¾÷